RSLS - ReShape Lifesciences Inc. Stock Price, Fair Value and News

0.18USD+0.01 (+5.88%)Delayed as of 03 May 2024, 12:10 pm ET

Market Summary

USD0.18+0.01

Delayedas of 03 May 2024, 12:10 pm

5.88%

RSLS Stock Price

View Fullscreen

RSLS RSI Chart

RSLS Valuation

Market Cap

4.0M

Price/Earnings (Trailing)

-0.35

Price/Sales (Trailing)

0.46

EV/EBITDA

0.05

Price/Free Cashflow

-0.24

RSLS Price/Sales (Trailing)

RSLS Profitability

Operating Margin

66.01%

EBT Margin

-130.62%

Return on Equity

-170.9%

Return on Assets

-106.79%

Free Cashflow Yield

-425.31%

RSLS Fundamentals

RSLS Revenue

Revenue (TTM)

8.7M

Rev. Growth (Yr)

-36.27%

Rev. Growth (Qtr)

-8.03%

RSLS Earnings

Earnings (TTM)

-11.4M

Earnings Growth (Yr)

89.69%

Earnings Growth (Qtr)

51.95%

Breaking Down RSLS Revenue

52 Week Range

0.172.80

(Low)(High)

Last 30 days

5.9%

Last 90 days

-10%

Trailing 12 Months

-92.8%

How does RSLS drawdown profile look like?

RSLS Financial Health

Current Ratio

2.73

Debt/Equity

0.06

Debt/Cashflow

-39.44

RSLS Investor Care

Shares Dilution (1Y)

785.59%

Diluted EPS (TTM)

-2.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	11.1M	10.4M	9.8M	8.7M
2022	12.8M	12.2M	11.3M	11.2M
2021	12.7M	14.6M	14.7M	13.6M
2020	2.3M	3.6M	6.9M	10.3M
2019	9.5M	7.2M	4.5M	3.3M
2018	9.7M	10.5M	10.7M	9.1M
2017	3.8M	5.0M	7.0M	9.9M
2016	4.2M	3.9M	3.6M	3.4M
2015	3.7M	3.8M	3.9M	4.0M
2014	0	0	0	3.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ReShape Lifesciences Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 25, 2023	stankovich thomas	sold	-35.37	0.27	-131	chief financial officer
Oct 11, 2023	stankovich thomas	sold	-36.27	0.93	-39.00	chief financial officer
Sep 01, 2023	stankovich thomas	sold	-105	0.89	-118	chief financial officer
Aug 24, 2023	stankovich thomas	sold	-55.38	1.42	-39.00	chief financial officer
Aug 04, 2023	stankovich thomas	sold	-154	1.43	-108	chief financial officer
Jul 06, 2023	stankovich thomas	sold	-155	1.47	-106	chief financial officer
Jun 30, 2023	stankovich thomas	bought	26,907	1.52	17,702	chief financial officer
May 31, 2023	stankovich thomas	sold	-236	2.41	-98.00	chief financial officer
Apr 30, 2023	stankovich thomas	sold	-226	2.36	-96.00	chief financial officer
Mar 31, 2023	stankovich thomas	sold	-283	2.6	-109	chief financial officer

Which funds bought or sold RSLS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-4,403	12,454	-%
Feb 26, 2024	Virtu Financial LLC	added	295	12,000	18,000	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-1,149	3,250	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-	1.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-34.00	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	added	447	14,207	18,872	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	14,742	14,742	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	new	-	5,288	5,288	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	18,195	18,195	-%

Are Funds Buying or Selling RSLS?

Are funds buying RSLS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RSLS

No. of Funds

Unveiling ReShape Lifesciences Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 17, 2024	schneid yair	525%	2,461,000	SC 13G
Mar 17, 2023	matthew joseph nachtrab revocable trust 2014	27.7%	133,853	SC 13D
Feb 15, 2023	foley & lardner/ fa	27.7%	133,853	SC 13D
Feb 14, 2023	armistice capital, llc	4.99%	25,395	SC 13G/A
Feb 15, 2022	armistice capital, llc	9.99%	1,973,807	SC 13G/A
Feb 14, 2022	interwest partners x lp	0%	6,250	SC 13G/A
Jun 22, 2021	armistice capital, llc	0%	0	SC 13D/A

Recent SEC filings of ReShape Lifesciences Inc.

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	8-K	Current Report
Apr 10, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Feb 26, 2024	8-K	Current Report
Jan 24, 2024	DEF 14A	DEF 14A

Peers (Alternatives to ReShape Lifesciences Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.3B	40.3B	-5.44%	-5.22%	32.76	4.57	-2.84%	-3.08%
BDX	69.5B	19.7B	-0.20%	-8.75%	52.15	3.53	4.82%	-17.56%
ALGN	21.5B	3.9B	-8.18%	-5.47%	48.35	5.57	3.42%	23.09%
BAX	18.8B	14.9B	-13.96%	-20.60%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	3.73%	21.66%	30.91	2.73	6.16%	35.06%
HSIC	8.8B	12.3B	-6.12%	-14.26%	21.19	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-15.06%	-39.81%	-12.8	3.05	-4.68%	82.43%
XRAY	5.9B	3.9B	-10.84%	-29.89%	-63.02	1.5	0.23%	91.03%
AXNX	3.4B	387.1M	-2.63%	29.53%	-215.05	8.84	30.82%	65.60%
PDCO	2.3B	6.6B	-3.75%	-4.94%	11.77	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-4.08%	-10.47%	-2.03	0.43	7.73%	-1066.14%
ANIK	409.1M	166.7M	6.81%	6.12%	-4.95	2.45	6.67%	-456.34%
ANGO	243.5M	324.0M	-1.78%	-29.87%	-1.27	0.75	-3.19%	-337.41%
APYX	49.2M	52.3M	-3.38%	-60.28%	-2.63	0.94	17.61%	19.28%
AEMD	3.6M	3.7M	-22.16%	302.94%	-0.29	0.96	5.77%	8.23%

ReShape Lifesciences Inc. News

Latest updates

ReShape Lifesciences Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-8.0%	1,982,000	2,155,000	2,254,000	2,287,000	3,110,000	2,798,000	2,892,000	2,440,000	3,142,000	3,708,000	3,529,000	3,221,000	4,211,000	3,602,000	1,702,000	780,000	780,000	333,000	400,000	1,775,000	2,036,000
Gross Profit	43.0%	1,842,000	1,288,000	1,194,000	1,224,000	1,600,000	2,101,000	1,883,000	1,218,000	1,776,000	2,135,000	2,153,000	2,284,000	2,273,000	2,281,000	837,000	239,000	160,000	-79,000	-293,000	543,000	532,000
Operating Expenses	-27.7%	3,737,500	5,168,000	5,170,000	6,855,000	18,293,000	14,402,000	11,127,000	9,331,000	39,292,500	16,554,000	5,842,000	4,541,000	5,063,000	4,453,000	3,835,000	5,150,000	5,135,000	3,663,000	6,120,000	8,643,000	9,192,000
S&GA Expenses	-21.9%	1,398,000	1,791,000	2,177,000	2,182,000	2,157,500	2,605,000	4,636,000	4,694,000	1,527,500	3,246,000	4,298,000	1,250,000	29,000	1,160,000	831,000	3,893,000	3,643,000	2,489,000	4,332,000	6,204,000	6,854,000
R&D Expenses	36.3%	739,000	542,000	581,000	453,000	462,000	583,000	747,000	745,000	270,000	1,425,000	103,000	571,000	898,000	859,000	465,000	1,257,000	1,492,000	1,174,000	1,788,000	2,439,000	2,338,000
EBITDA Margin	50.7%	-1.29	-2.62	-3.32	-3.66	-4.09	-5.94	-5.87	-5.15	-4.62	-1.47	-1.48	-1.71	-2.10	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	296,000	-	-	-	-	-	19,000	137,000	358,000	205,000	169,000
Income Taxes	933.3%	31,000	3,000	4,000	14,000	-56,000	-363,000	9,000	30,000	-297,000	-30,000	28,000	25,000	-82,500	-39,000	-50,000	-	-	-	-	-	-
Earnings Before Taxes	52.8%	-1,667,000	-3,531,000	-3,489,000	-2,648,000	-16,525,000	-12,549,000	-9,435,000	-8,085,000	-37,546,000	-17,164,000	-3,861,000	-4,849,000	-	-5,218,000	-3,654,000	-	-	-	-	-	-
EBT Margin	51.1%	-1.31	-2.67	-3.37	-3.71	-4.15	-6.00	-5.93	-5.20	-4.66	-1.49	-1.50	-1.71	-2.12	-	-	-	-	-	-	-	-
Net Income	52.0%	-1,698,000	-3,534,000	-3,493,000	-2,662,000	-16,469,000	-12,186,000	-9,444,000	-8,115,000	-37,249,000	-17,134,000	-3,889,000	-4,874,000	-8,061,000	-5,179,000	-3,604,000	-5,261,000	-4,913,000	-3,706,000	-6,767,000	-8,290,000	-8,756,000
Net Income Margin	50.8%	-1.31	-2.67	-3.33	-3.68	-4.11	-5.94	-5.91	-5.18	-4.64	-2.31	-1.51	-1.71	-2.15	-	-	-	-	-	-	-	-
Free Cashflow	11.6%	-2,457,000	-2,780,000	-6,662,000	-5,061,000	-2,829,000	-5,273,000	-6,422,000	-7,378,000	-3,426,000	-7,800,000	-2,188,000	-1,961,000	-1,816,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	36.2%	10,663	7,827	11,852	16,352	11,142	26,485	40,357	45,623	52,531	90,790	120,013	17,343	37,061	11,962	13,873	19,229	20,393	24,657	19,199	32,368	30,386
Current Assets	39.2%	10,296	7,399	10,544	15,231	9,911	13,257	19,171	23,311	29,938	37,273	65,303	12,794	8,944	9,031	10,775	15,570	18,235	22,349	17,021	29,912	28,647
Cash Equivalents	217.5%	4,600	1,449	4,567	8,983	3,855	6,245	11,544	15,460	22,815	29,293	40,213	1,946	3,007	1,907	1,576	8,915	2,985	19,380	13,513	24,684	21,187
Inventory	16.8%	3,741	3,204	3,268	3,493	3,611	4,171	4,226	3,998	3,003	3,206	2,894	-	2,244	-	-	1,408	1,936	2,048	2,107	1,860	1,580
Net PPE	-14.3%	60.00	70.00	659	672	698	896	887	1,371	1,454	1,602	1,588	891	584	982	1,055	2,159	1,081	1,117	1,038	1,222	1,739
Goodwill	-	-	-	-	-	-	-	-	-	1,900	22,950	23,520	-	-	-	-	-	-	-	-	-	-
Liabilities	-15.7%	4,000	4,744	5,114	8,594	7,481	7,532	9,581	8,664	8,197	11,478	61,881	7,245	22,573	6,040	6,695	8,157	4,544	4,592	10,812	25,850	17,279
Current Liabilities	-15.5%	3,777	4,469	4,404	7,602	7,481	7,532	9,209	8,170	7,530	10,336	60,496	6,863	11,605	5,050	5,599	7,188	3,977	3,905	10,090	25,031	17,231
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	430	430	430	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,000	19,952	9,930
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	430	430	430	-	-	-	-	-	-
Shareholder's Equity	116.1%	6,663	3,083	6,738	7,758	3,661	18,953	30,776	36,959	44,334	79,312	58,132	12,708	14,488	17,083	19,153	21,568	24,107	20,065	8,376	6,518	13,107
Retained Earnings	-0.3%	-635,600	-633,876	-630,342	-626,849	-624,187	-607,718	-595,532	-586,088	-577,973	-540,724	-523,590	-188,931	-514,827	-183,439	-181,900	-177,691	-172,430	-167,500	-163,811	-157,044	-148,754
Additional Paid-In Capital	0.8%	642,302	637,050	637,172	634,697	627,935	626,739	626,380	623,118	622,399	620,125	581,823	199,019	529,435	189,353	189,049	188,755	188,271	187,574	172,162	163,538	161,859
Shares Outstanding	579.4%	23,457	3,453	3,452	2,649	519	403	386	371	357	342	85.00	79.00	70.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	10,658	-	-	-	37,324	-	-	-	4,300	-	-	-	16,600	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	11.6%	-2,457	-2,780	-6,662	-5,061	-2,829	-5,273	-6,422	-7,378	-3,426	-7,800	-2,188	-1,961	-1,762	-976	-998	-4,814	-4,879	-3,989	-4,356	-9,642	-5,415
Share Based Compensation	-49.1%	110	216	218	222	240	-1.50	1,489	719	2,256	10,234	-364	101	298	259	292	470	683	659	536	1,105	1,083
Cashflow From Investing	-	-	-	-3.00	-7.00	-79.00	-33.00	18.00	2.00	-3,067	-89.00	5,130	-119	-2,160	-148	244	-326	-150	-24.00	-1.00	2,531	5,185
Cashflow From Financing	1715.7%	5,461	-338	2,250	10,201	638	3.00	-	-	-	-3,033	35,332	1,000	5,069	1,500	4,506	-	-296	9,880	-6,814	10,608	-135

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RSLS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Consolidated Statements of Operations
Revenue	$ 8,678	$ 11,240
Cost of revenue	3,130	4,438
Gross profit	5,548	6,802
Operating expenses:
Sales and marketing	7,548	14,093
General and administrative	10,324	17,250
Research and development	2,315	2,537
Impairment of long-lived assets	777	18,744
(Gain) loss on disposal of assets, net	(33)	529
Total operating expenses	20,931	53,153
Operating loss	(15,383)	(46,351)
Other expense (income), net:
Interest (income) expense, net	(26)	113
Gain on changes in fair value of liability warrants	(3,878)
(Gain) loss on foreign currency exchange, net	(22)	141
Other	(122)	(11)
Loss before income tax provision	(11,335)	(46,594)
Income tax expense (benefit)	52	(380)
Net loss	$ (11,387)	$ (46,214)
Net loss per share - basic and diluted:
Net loss per share - basic (in dollars per share)	$ (1.91)	$ (108.90)
Net loss per share - diluted (in dollars per share)	$ (1.91)	$ (108.90)
Shares used to compute basic net loss per share (in shares)	5,956,549	424,390
Shares used to compute diluted net loss per share (in shares)	5,956,549	424,390

RSLS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,459	$ 3,855
Restricted cash	100	100
Accounts and other receivables (net of allowance for doubtful accounts of $804 and $410 respectively)	1,659	2,180
Inventory	3,741	3,611
Prepaid expenses and other current assets	337	165
Total current assets	10,296	9,911
Property and equipment, net	60	698
Operating lease right-of-use assets	250	171
Deferred tax asset, net	28	56
Other intangible assets, net		260
Other assets	29	46
Total assets	10,663	11,142
Current liabilities:
Accounts payable	1,689	1,926
Accrued and other liabilities	1,814	5,040
Warranty liability, current	163	344
Operating lease liabilities, current	111	171
Total current liabilities	3,777	7,481
Operating lease liabilities, noncurrent	151
Common stock warrant liability	72
Total liabilities	4,000	7,481
Commitments and contingencies (Note 14)
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized at December 31, 2023 and December 31, 2022; 23,457,047 and 519,219 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	23	1
Additional paid-in capital	642,302	627,935
Accumulated deficit	(635,574)	(624,187)
Accumulated other comprehensive loss	(88)	(88)
Total stockholders' equity	6,663	3,661
Total liabilities and stockholders' equity	10,663	11,142
Series C convertible preferred stock
Stockholders' equity:
Preferred stock, 10,000,000 shares authorized: Series C convertible preferred stock, $0.001 par value; 95,388 shares issued and outstanding at December 31, 2023 and December 31, 2022

About ReShape Lifesciences Inc.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

CEO	Mr. Paul F. Hickey
WEBSITE	reshapelifesciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	40

ReShape Lifesciences Inc. Frequently Asked Questions

What is the ticker symbol for ReShape Lifesciences Inc.? What does RSLS stand for in stocks?

RSLS is the stock ticker symbol of ReShape Lifesciences Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ReShape Lifesciences Inc. (RSLS)?

As of Thu May 02 2024, market cap of ReShape Lifesciences Inc. is 3.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RSLS stock?

You can check RSLS's fair value in chart for subscribers.

What is the fair value of RSLS stock?

You can check RSLS's fair value in chart for subscribers. The fair value of ReShape Lifesciences Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ReShape Lifesciences Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RSLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ReShape Lifesciences Inc. a good stock to buy?

The fair value guage provides a quick view whether RSLS is over valued or under valued. Whether ReShape Lifesciences Inc. is cheap or expensive depends on the assumptions which impact ReShape Lifesciences Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RSLS.

What is ReShape Lifesciences Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, RSLS's PE ratio (Price to Earnings) is -0.35 and Price to Sales (PS) ratio is 0.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RSLS PE ratio will change depending on the future growth rate expectations of investors.